Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims.

- Į. (Currently amended) A method of stimulating angiogenesis in a mammal, comprising administering to said mammal an effective amount of a polynucleotide selected from the group consisting of:
 - a polynucleotide encoding SEQ ID NO:2; (a)
 - a polynucleotide encoding SEQ ID NO:7;
 - a polynucleotide encoding the CTGF-2 polypeptide encoded by the cDNA (<u>be</u>) contained in ATCC Deposit No. 75804; and
 - a polynucleotide encoding a CTGF-2 polypeptide fragment with angiogenic (<u>c</u>4) activity.
- 2. (Original) The method of claim 1, wherein said administered polynucleotide is contained in an adenoviral vector.
- 3. (Original) The method of claim 1, wherein the mammal has ischemia.
- The method of claim 1, wherein the mammal has restenosis. 4. (Original)
- 5. The method of claim 1, wherein said polynucleotide is delivered to the (Original) heart.
- 6. (Previously presented) The method of claim 2, wherein the adenoviral vector is pTG14550 deposited with the Pasteur Institute as deposit number CNCM I-2695.
- 7. (Original) The method of claim 1, wherein the polynucleotide is administered intramuscularly.
- 8. (Original) The method of claim 1, wherein the polynucleotide is administered intravenously.
- 9. The method of claim 1, wherein the mammal is treated for limb (Original) revascularization.
- 10. The method of claim 9, wherein the limb is a leg. (Original)

F-918

- The method of claim 9, wherein the limb is an arm. 11. (Original)
- The method of claim 1, wherein the mammal is human. 12. (Original)
- The method of claim 1, wherein the polynucleotide is administered with a 13. (Original) pharmaceutically acceptable carrier selected from the group consisting of:
 - (a) saline.
 - buffered saline. (b)
 - (c) dextrose,
 - (d) water,
 - (e) glycerol,
 - **(f)** ethanol, and
 - combinations of the above. (g)
- (Currently amended) The method of claim 1, wherein the polynucleotide or thereof is 14. fused to a human serum albumin polynucleotide.
- 15-27. (Cancelled)
- 28. (Previously presented) The method of claim 2, wherein the mammal has ischemia.
- 29. (Previously presented) The method of claim 2, wherein the mammal has restenosis.
- 30. (Previously presented) The method of claim 2, wherein said polynucleotide is delivered to the heart.
- 31. (Previously presented) The method of claim 2, wherein the polynucleotide is administered intramuscularly.
- The method of claim 2, wherein the polynucleotide is 32. (Previously presented) administered intravenously.
- 33. (Previously presented) The method of claim 2, wherein the mammal is treated for limb revascularization.

3

34. (Previously presented) The method of claim 2, wherein the mammal is human.

Docket No: PF126P2

35.	(Previously presented)	The method of claim 2, wherein the polynucleotide is			
administered with a pharmaceutically acceptable carrier selected from the group consisting of:					
	(a) saline,				
	(b) buffered saline,				
	(c) dextrose,				
	(d) water,				
	(e) glycerol,				
	(f) ethanol, and				
	(g) combinations of the	above.			
36.	(Previously presented)	The method of claim 2, wherein the polynucleotide is fused			
to a human serum albumin polynucleotide.					
37.	(Previously presented)	The method of claim 1, wherein the mammal has			
cardio	ovascular disease.				
20	(D. a. Con also massacts 1)	The weather destablished 2 in housing the accounted has			
38.	(Previously presented)	The method of claim 2, wherein the mammal has			
cardio	ovascular disease.				
39.	(Previously presented)	The method of claim 1, wherein the mammal is treated for			
woun	d healing.				
40.	(Previously presented)	The method of claim 2, wherein the mammal is treated for			
wound healing.					
41.	(Previously presented)	The method of claim 1, wherein the mammal is treated for			
regeneration of tissues.					
108011	eidlett at Heedes.				
4 2.	(Previously presented)	The method of claim 6, wherein the mammal is treated for			
regeneration of tissues.					
43.	(Previously presented)	The method of claim 6, wherein the mammal has ischemia.			
44.	(Previously presented)	The method of claim 6, wherein the mammal has			
rester	•	ware strainted as estimated at themselves preventions some			
1-21-1					
45.	(Previously presented)	The method of claim 6, wherein said polynucleotide is			
delivered to the heart.					

Application No.: 09/901,910

098439	T-693	P.06/09	F-918

	iously presented) intramuscularly	The method of claim 6, wherein the polynucleotide is
-	iously presented) intravenously.	The method of claim 6, wherein the polynucleoride is
48. (Previously presented) limb revascularization.		The method of claim 6, wherein the mammal is treated for
49. (Prev	iously presented)	The method of claim 48, wherein the limb is a leg.
50. (Prev	iously presented)	The method of claim 48, wherein the limb is an arm.
51. (Prev	iously presented)	The method of claim 6, wherein the mammal is human.
· .	iously presented) with a pharmaceutically saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations of the	The method of claim 6, wherein the polynucleotide is y acceptable carrier selected from the group consisting of:
53. (Prev	iously presented)	The method of claim 1, wherein the polynucleotide is (a).
54. (Prev	iously presented)	The method of claim 1, wherein the polynucleotide is (b).
55. (Prev.	iously presented)	The method of claim 1, wherein the polynucleotide is (c).

56. (Cancelled)